Search results for "galant"

showing 10 items of 25 documents

Von der symptomatischen zur kausalen Therapie?

2009

Until today the pharmacological therapy of Alzheimer’s disease (AD) is still limited to symptomatic temporary improvement or stabilization of cognitive performance and activities of daily living, and the reduction of neuropsychiatric symptoms of the disease. Available symptomatic treatment options are the acetylcholinesterase inhibitors (ACh-I) donepezil, galantamine, rivastigmine, and the partial N-Methyl-D-Aspartat-(NMDA)-antagonist memantine. Further substances with symptomatic targets, especially selective acetylcholine and histamine receptors, are currently under development. Numerous of disease-modifying substances mainly targeting components of the amyloidogenic pathway of AD are pre…

Rivastigminebusiness.industryMemantineDiseaseBioinformaticsAcetylcholinesteraseClinical trialPsychiatry and Mental healthchemistry.chemical_compoundPharmacotherapyNeurologychemistryGalantamineMedicineNeurology (clinical)businessDonepezilNeurosciencemedicine.drugFortschritte der Neurologie · Psychiatrie
researchProduct

Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity

2004

Galantamine is a plant alkaloid that is used in the treatment of Alzheimer's disease. We have studied the effects of galantamine on beta-amyloid-enhanced glutamate toxicity using primary rat cultured cortical neurons. Nicotine and galantamine alone, and in combination, protected neurons against this neurotoxicity. The protection was not blocked by alpha4beta2 nicotinic acetylcholine receptor (nAChR) antagonists, but was partially blocked by alpha7 nAChR antagonists. Galantamine induced phosphorylation of Akt, an effector of phosphatidylinositol 3-kinase (PI3K), while PI3K inhibitors blocked the protective effect and Akt phosphorylation. The antibody FK1, which selectively blocks the alloste…

Cell SurvivalBiophysicsGlutamic AcidReceptors NicotinicPharmacologycomplex mixturesBiochemistryNeuroprotectionmedicineGalantamineAnimalsDrug InteractionsMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwayCerebral CortexNeuronsAmyloid beta-PeptidesDose-Response Relationship DrugGalantamineChemistryGlutamate receptorNeurotoxicityCell Biologymedicine.diseaseRatsNeuroprotective AgentsNicotinic agonistnervous systemPhosphorylationmedicine.drugBiochemical and Biophysical Research Communications
researchProduct

Fontenelle ou la tendresse philosophe . Introduction

2015

International audience; Philosophe, écrivain, mathématicien, Académicien, Fontenelle (1657-1757) produit une œuvre dont ce volume montre l’unité dans une écriture philosophique définie comme réflexion sur le mouvement ordinaire de la pensée et sur l’historicité des idées, à partir de toutes les œuvres de l’esprit et de la culture. Cette édition scientifique de plus de vingt œuvres et d’extraits de l’Histoire de l’Académie royale des sciences, précédée d’un essai introductif, montre une pratique réflexive des discours qui vise l’émancipation de l’esprit par la réappropriation de ses propres œuvres. Fontenelle y ajoute un esprit singulier qui consiste à éveiller des idées chez son interlocute…

Lumières[SHS.PHIL] Humanities and Social Sciences/PhilosophyélogesFontenelle[SHS.PHIL]Humanities and Social Sciences/PhilosophyAcadémie royale des sciencesPhilosophiematérialismegalanterie
researchProduct

Melampsora allii-fragilis f. sp. galanthi-fragilis reported for first time to cause rust on Galanthus plicatus in Latvia

2010

In Europe, Melampsora allii-fragilis f. sp. galanthi-fragilis (syn. Melampsora galanthi-fragilis) has been reported on leaves of snowdrop (Galanthus nivalis) in Romania (Savulescu, 1953; Bagyanarayana, 2005) and on Galanthus plicatus in Ukraine (Gutsevich, 1952). The GBIF Database has additional records of this fungus on G. nivalis from Austria, Czech Republic and France but the USDA SMML Specimens Database has also records from Hungary and Poland. According to this database, the established distribution area of M. allii-fragilis f. sp. galanthi-fragilis is ‘Central Europe’. Melampsora allii-fragilis f. sp. galanthi-fragilis belongs to the heteroecious rust fungi that require two hosts to c…

Salix fragilisbiologyPlant ScienceFungusMelampsoraHorticulturebiology.organism_classificationSporeHerbariumHeteroeciousBotanyGeneticsTaxonomy (biology)Agronomy and Crop ScienceGalanthus nivalisPlant Pathology
researchProduct

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

2001

Cholinesterase inhibitors are the only approved drug treatment for patients with mild to moderately severe Alzheimer's disease. Interestingly, the clinical potency of these drugs does not correlate well with their activity as cholinesterase inhibitors, nor is their action as short lived as would be expected from purely symptomatic treatment. A few cholinesterase inhibitors, including galantamine, produce beneficial effects even after drug treatment has been terminated. These effects assume modes of action other than mere esterase inhibition and are capable of inducing systemic changes. We have recently discovered a mechanism that could account, at least in part, for the above-mentioned unex…

medicine.medical_specialtyPatch-Clamp TechniquesReceptors NicotinicPharmacologyCell LineMiceAllosteric RegulationAlzheimer DiseaseInternal medicinemedicineGalantamineAnimalsHumansNootropic AgentsBiological PsychiatryCholinesteraseAcetylcholine receptorNeuronsbiologyGalantamineChemistryNicotinic acetylcholine receptorNicotinic agonistEndocrinologyMechanism of actionTacrinebiology.proteinCholinesterase Inhibitorsmedicine.symptomAllosteric SiteAcetylcholinemedicine.drugBiological Psychiatry
researchProduct

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for mul…

2016

Abstract Background Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports. We aimed to systematically review the efficacy and safety of AceI and memantine across multiple outcome dimensions in BD. Methods Systematic PubMed and SCOPUS search until 04/17/2015 without language restrictions. Included were randomized controlled trials (RCTs), open label studies and case series of AceI or memantine in BD patients reporting quantitative data on depression, mania, psychotic symptoms, global functioning, or cognitive performance. We summarized results using a best-…

Malelaw.inventionpsychosis.0302 clinical medicinePiperidinesRandomized controlled triallawDonepezilDonepezilRandomized Controlled Trials as Topicbipolar disorderClinical Trials as TopicEvidence-Based MedicineDepressionMemantineMiddle AgedManiaPsychiatry and Mental healthClinical PsychologyTreatment Outcomeacetylcholinesterase inhibitorsdepressionIndansFemalemedicine.symptomPsychologyManiamedicine.drugAdultmedicine.medical_specialtyBipolar disorderPlaceboBipolar disorder Acetylcholinesterase inhibitors Memantine Depression Mania Psychosis03 medical and health sciencesmaniaMemantineInternal medicinemedicineGalantamineHumansBipolar disorderAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis.PsychiatryDepressive DisorderGalantaminePsychosismedicine.disease030227 psychiatryAcetylcholinesterase inhibitorsMoodPsychotic DisordersAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis; Psychiatry and Mental Health; Clinical PsychologyCase-Control StudiesmemantineCholinesterase InhibitorsExcitatory Amino Acid Antagonists030217 neurology & neurosurgeryJournal of Affective Disorders
researchProduct

New Prospectives in the Delivery of Galantamine for Elderly Patients Using the IntelliDrug Intraoral Device: In Vivo Animal Studies

2009

The transbuccal delivery of drugs could assist several categories of chronic, especially elderly, patients in adhering to a correct dosage regimen. In particular, patients suffering from dementia have several difficulties in following the prescribed dosage, in addition to problems associated with swallowing tablets. Galantamine is currently used for treating patients with mild to moderate Alzheimer's-type dementia. The transbuccal delivery of this drug could be an interesting non- invasive and safe administration route. Several studies have been performed in vitro and ex vivo within the framework of a European Commission funded Project (IntelliDrug-FP6), aimed at developing a device which w…

Drugmedicine.medical_specialtySwinemedia_common.quotation_subjectSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralPilot ProjectsRoute of administrationDrug Delivery SystemsIn vivoOral administrationDrug DiscoveryGalantaminemedicineAnimalsHumansAgedmedia_commonPharmacologyGalantaminebusiness.industryMouth MucosaTransbuccal drug delivery Alzheimer disease GalantamineAdministration BuccalBuccal administrationSurgeryRegimenSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryFemalebusinessmedicine.drugCurrent Pharmaceutical Design
researchProduct

Buccal delivery in treatment of Alzheimer disease: enhancement of galantamine absorption

2009

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoBuccal Delivery Alzheimer diisease Galantamine
researchProduct

Psychosis as adverse effect of cholinesterase inhibitors: two case reports of probable Alzheimer disease in treatment with galantamine

2012

Settore MED/26 - Neurologiagalantamine Alzheimer disease
researchProduct

Galantamine permeation through buccal mucosa: studies on reconstituted human oral epithelium and porcine tissue

2008

HOEGalantaminePorcine buccal mucosaTransbuccal permeation
researchProduct